SG Americas Securities LLC boosted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 9.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,369 shares of the biopharmaceutical company’s stock after purchasing an additional 2,120 shares during the period. SG Americas Securities LLC’s holdings in Intra-Cellular Therapies were worth $1,290,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently added to or reduced their stakes in ITCI. JPMorgan Chase & Co. lifted its position in Intra-Cellular Therapies by 11.7% in the first quarter. JPMorgan Chase & Co. now owns 157,144 shares of the biopharmaceutical company’s stock valued at $9,615,000 after purchasing an additional 16,454 shares during the period. Bank of New York Mellon Corp increased its holdings in Intra-Cellular Therapies by 5.2% in the first quarter. Bank of New York Mellon Corp now owns 385,508 shares of the biopharmaceutical company’s stock valued at $23,591,000 after buying an additional 18,999 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in Intra-Cellular Therapies in the first quarter valued at about $349,000. PNC Financial Services Group Inc. increased its holdings in Intra-Cellular Therapies by 25.6% in the first quarter. PNC Financial Services Group Inc. now owns 5,909 shares of the biopharmaceutical company’s stock valued at $363,000 after buying an additional 1,204 shares in the last quarter. Finally, Natixis Advisors L.P. increased its holdings in Intra-Cellular Therapies by 71.3% in the first quarter. Natixis Advisors L.P. now owns 18,165 shares of the biopharmaceutical company’s stock valued at $1,112,000 after buying an additional 7,558 shares in the last quarter. Institutional investors and hedge funds own 86.95% of the company’s stock.
Intra-Cellular Therapies Stock Performance
ITCI stock opened at $61.04 on Thursday. The stock has a market capitalization of $5.82 billion, a P/E ratio of -22.44 and a beta of 1.15. Intra-Cellular Therapies, Inc. has a one year low of $42.01 and a one year high of $63.50. The company has a 50 day moving average price of $52.18 and a two-hundred day moving average price of $50.67.
Analysts Set New Price Targets
A number of research analysts have issued reports on ITCI shares. Morgan Stanley started coverage on shares of Intra-Cellular Therapies in a report on Thursday, April 20th. They issued an “overweight” rating and a $80.00 target price for the company. Royal Bank of Canada dropped their target price on shares of Intra-Cellular Therapies from $75.00 to $71.00 and set an “outperform” rating for the company in a report on Thursday, March 2nd. StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a research note on Thursday, March 16th. They set a “hold” rating for the company. Canaccord Genuity Group raised their price objective on shares of Intra-Cellular Therapies from $93.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, March 29th. Finally, Needham & Company LLC reissued a “buy” rating and set a $66.00 price objective on shares of Intra-Cellular Therapies in a research note on Tuesday, April 18th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $74.00.
Insider Buying and Selling at Intra-Cellular Therapies
In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 53,968 shares of Intra-Cellular Therapies stock in a transaction on Friday, February 17th. The shares were sold at an average price of $49.83, for a total value of $2,689,225.44. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 53,968 shares of Intra-Cellular Therapies stock in a transaction on Friday, February 17th. The shares were sold at an average price of $49.83, for a total value of $2,689,225.44. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Sharon Mates sold 41,770 shares of Intra-Cellular Therapies stock in a transaction on Friday, March 10th. The shares were sold at an average price of $43.15, for a total transaction of $1,802,375.50. Following the transaction, the chief executive officer now owns 1,130,309 shares in the company, valued at approximately $48,772,833.35. The disclosure for this sale can be found here. Insiders have sold a total of 278,827 shares of company stock worth $13,226,937 in the last quarter. 3.70% of the stock is owned by insiders.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.
See Also
- Get a free copy of the StockNews.com research report on Intra-Cellular Therapies (ITCI)
- Texas Instruments: Another Reason To Take Profits In Chip Stocks?
- 11 Best Growth Stocks to Buy Now
- How to Invest in GTE Technology
- Chipotle Mexican Grill Is Still A Tasty Investment
- Why Do Tech Stocks Go Down When Interest Rates Rise?
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
